Arrowhead Pharmaceuticals (ARWR) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04280A1007
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a United States-based company focused on developing innovative medicines to treat challenging diseases. Among its diverse pipeline of products are Plozasiran, Zodasiran, ARO-PNPLA3, ARO-RAGE, and ARO-MUC5AC, targeting conditions like hypertriglyceridemia, dyslipidemia, and pulmonary diseases.
Additionally, Arrowhead Pharmaceuticals is actively working on treatments such as ARO-MMP7 for idiopathic pulmonary fibrosis, ARO-DUX4 for muscular dystrophy, ARO-SOD1 for ALS, and ARO-C3 for complement-mediated renal diseases, showcasing a commitment to addressing a wide range of health issues.
Collaborating with industry leaders like Janssen Pharmaceuticals, Takeda Pharmaceutical, Amgen, and GlaxoSmithKline, Arrowhead Pharmaceuticals leverages its expertise to advance treatments like JNJ-3989 for hepatitis B, Olpasiran for reducing apolipoprotein A production, and Fazirsiran for liver disease associated with alpha-1 antitrypsin deficiency.
Established in 2003 and located in Pasadena, California, Arrowhead Pharmaceuticals is dedicated to pushing the boundaries of medical innovation. To learn more about their work, visit their website at https://arrowheadpharma.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ARWR Stock Overview
| Market Cap in USD | 2,741m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 1993-06-16 |
ARWR Stock Ratings
| Growth 5y | -0.92 |
| Fundamental | -85.0 |
| Dividend | - |
| Rel. Performance vs Sector | -4.65 |
| Analysts | 4.21/5 |
| Fair Price Momentum | 19.01 USD |
| Fair Price DCF | - |
ARWR Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
ARWR Growth Ratios
| Growth 12m | -37.53% |
| Growth Correlation 12m | -38% |
| Growth Correlation 3m | -71% |
| CAGR 5y | 3.81% |
| Sharpe Ratio 12m | -0.69 |
| Alpha vs SP500 12m | -66.94 |
| Beta vs SP500 5y weekly | 1.29 |
| ValueRay RSI | 14.44 |
| Volatility GJR Garch 1y | 62.64% |
| Price / SMA 50 | -21% |
| Price / SMA 200 | -23.78% |
| Current Volume | 617.1k |
| Average Volume 20d | 876.1k |
External Links for ARWR Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 27, 2024, the stock is trading at USD 22.12 with a total of 617,126 shares traded.
Over the past week, the price has changed by -0.94%, over one month by -20.55%, over three months by -32.46% and over the past year by -37.73%.
According to ValueRays Forecast Model, ARWR Arrowhead Pharmaceuticals will be worth about 21.3 in April 2025. The stock is currently trading at 22.12. This means that the stock has a potential downside of -3.53%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 55.4 | 150 |
| Analysts Target Price | 55.6 | 151 |
| ValueRay Target Price | 21.3 | -3.53 |